AllSquare Wealth Management LLC acquired a new stake in Bristol-Myers Squibb Co (NYSE:BMY) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 2,100 shares of the biopharmaceutical company’s stock, valued at approximately $134,000.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Renaissance Technologies LLC grew its position in shares of Bristol-Myers Squibb by 108.5% during the 2nd quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock worth $751,563,000 after buying an additional 7,020,200 shares during the period. Franklin Resources Inc. grew its position in shares of Bristol-Myers Squibb by 185.2% during the 2nd quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock worth $339,830,000 after buying an additional 3,960,191 shares during the period. Jennison Associates LLC grew its position in shares of Bristol-Myers Squibb by 16.2% during the 3rd quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock worth $1,711,689,000 after buying an additional 3,735,453 shares during the period. Janus Henderson Group PLC grew its position in shares of Bristol-Myers Squibb by 2,990.5% during the 2nd quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock worth $202,494,000 after buying an additional 3,516,536 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Bristol-Myers Squibb by 42,071.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,331,549 shares of the biopharmaceutical company’s stock worth $185,634,000 after buying an additional 3,323,649 shares during the period. Hedge funds and other institutional investors own 69.67% of the company’s stock.
Bristol-Myers Squibb Co (NYSE:BMY) opened at $62.81 on Friday. The stock has a market cap of $102,800.00, a P/E ratio of 24.73, a P/E/G ratio of 2.29 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Co has a 1-year low of $46.01 and a 1-year high of $66.10.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a yield of 2.55%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s payout ratio is currently 62.99%.
In related news, Director Theodore R. Samuels II purchased 4,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were purchased at an average price of $62.30 per share, with a total value of $249,200.00. Following the completion of the purchase, the director now owns 22,000 shares in the company, valued at approximately $1,370,600. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the transaction, the executive vice president now directly owns 9,251 shares in the company, valued at approximately $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by insiders.
Several equities research analysts have recently commented on the stock. Cowen reiterated a “hold” rating and set a $65.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, September 19th. Jefferies Group reiterated a “buy” rating and set a $72.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. Piper Jaffray Companies reiterated a “hold” rating and set a $60.00 price target on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, Vetr upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 price target for the company in a research report on Wednesday, September 27th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company. Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $65.05.
ILLEGAL ACTIVITY NOTICE: “AllSquare Wealth Management LLC Acquires Shares of 2,100 Bristol-Myers Squibb Co (BMY)” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/01/14/allsquare-wealth-management-llc-acquires-shares-of-2100-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.